Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro

  • Authors:
    • Yanhong Yang
    • Wenwen Zhou
    • Jiandong Wu
    • Lixin Yao
    • Lei Xue
    • Qianyi Zhang
    • Zhenzhen Wang
    • Xiaoyu Wang
    • Shu Dong
    • Jiangman Zhao
    • Duanduan Yin
  • View Affiliations

  • Published online on: February 1, 2018     https://doi.org/10.3892/ol.2018.7923
  • Pages: 5280-5284
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nimotuzumab, a humanized IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR), increases radiosensitivity in lung cancer. Cisplatin is an effective antitumor agent in lung cancer. In the present study, the antitumor activity of nimotuzumab combined with cisplatin was investigated in A549 lung cancer cells. Viability, cell cycle distribution and cyclin D1 expression were assessed following treatment with nimotuzumab alone, cisplatin alone, nimotuzumab in combination with cisplatin, and nimotuzumab followed sequentially by cisplatin. The inhibitory effect on cell viability of nimotuzumab sequentially followed by cisplatin was higher compared with cisplatin alone (82.17±1.62 vs. 56.97±1.42%). Compared with treatment by cisplatin alone, cell cycle analysis by flow cytometry demonstrated that the percentage of cells in the G0/G1 phase was increased when A549 cells were treated with nimotuzumab followed sequentially by cisplatin (P<0.01). However, the proportion of cells in G0/G1 phase was decreased when A549 cells were treated with nimotuzumab and cisplatin simultaneously compared with cisplatin alone (P<0.05). Cyclin D1 expression was decreased in all chemotherapy treatment groups; the most significant decrease was in A549 cells treated with nimotuzumab followed sequentially by cisplatin. Nimotuzumab may enhance the antitumor activity of cisplatin on A549 cells. The cell cycle arrest at G0/G1 observed may have been due to decreased cyclin D1 levels. Potential antagonism was identified when A549 cells were treated with nimotuzumab and cisplatin simultaneously, indicating that targeted therapy may be more effective when administered prior to conventional chemotherapy.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang Y, Zhou W, Wu J, Yao L, Xue L, Zhang Q, Wang Z, Wang X, Dong S, Zhao J, Zhao J, et al: Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro. Oncol Lett 15: 5280-5284, 2018.
APA
Yang, Y., Zhou, W., Wu, J., Yao, L., Xue, L., Zhang, Q. ... Yin, D. (2018). Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro. Oncology Letters, 15, 5280-5284. https://doi.org/10.3892/ol.2018.7923
MLA
Yang, Y., Zhou, W., Wu, J., Yao, L., Xue, L., Zhang, Q., Wang, Z., Wang, X., Dong, S., Zhao, J., Yin, D."Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro". Oncology Letters 15.4 (2018): 5280-5284.
Chicago
Yang, Y., Zhou, W., Wu, J., Yao, L., Xue, L., Zhang, Q., Wang, Z., Wang, X., Dong, S., Zhao, J., Yin, D."Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro". Oncology Letters 15, no. 4 (2018): 5280-5284. https://doi.org/10.3892/ol.2018.7923